Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 717,710 | 2,574,000 | 1,814,640 | 1,143,605 | 437,531 |
| Depreciation Amortization | 74,326 | 278,000 | 204,575 | 133,579 | 66,167 |
| Income taxes - deferred | 39,301 | -39,000 | 21,374 | 21,966 | 51,385 |
| Accounts receivable | -231,781 | 198,000 | 160,831 | 180,167 | -196,531 |
| Accounts payable and accrued liabilities | 30,792 | 117,000 | 146,458 | 230,614 | 107,652 |
| Other Working Capital | -233,448 | 108,000 | 302,392 | 350,907 | -159,461 |
| Other Operating Activity | 275,201 | -41,000 | -161,282 | -317,218 | 146,226 |
| Operating Cash Flow | $672,101 | $3,195,000 | $2,488,988 | $1,743,620 | $452,969 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 10,243 | -672,000 | -992,313 | -540,853 | 56,719 |
| PPE Investments | -38,854 | -397,000 | -127,175 | -60,591 | -23,199 |
| Net Acquisitions | -378,645 | -10,752,000 | -10,751,640 | -10,751,640 | -10,751,640 |
| Purchase Of Investment | N/A | -25,000 | -25,000 | -25,000 | -25,000 |
| Other Investing Activity | 0 | 0 | 8 | 4 | 0 |
| Investing Cash Flow | $-407,256 | $-11,846,000 | $-11,896,120 | $-11,378,080 | $-10,743,120 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 100,771 | 2,358,000 | 2,144,733 | 2,144,733 | 2,144,733 |
| Debt Repayment | -347,916 | -1,839,000 | -1,052,167 | -702,151 | -350,612 |
| Common Stock Issued | 86,049 | 466,000 | 350,264 | 201,791 | 132,530 |
| Common Stock Repurchased | -82,239 | -667,000 | -467,000 | -261,791 | -20,770 |
| Other Financing Activity | 44,334 | 245,000 | 97,367 | -1,871 | -50,291 |
| Financing Cash Flow | $-199,001 | $563,000 | $1,073,197 | $1,380,711 | $1,855,590 |
| Exchange Rate Effect | -5,566 | 8,000 | 872 | -4,528 | 2,722 |
| Beginning Cash Position | 1,803,694 | 9,884,000 | 9,883,777 | 9,883,777 | 9,883,777 |
| End Cash Position | 1,863,972 | 1,804,000 | 1,550,710 | 1,625,500 | 1,451,942 |
| Net Cash Flow | $60,278 | $-8,080,000 | $-8,333,067 | $-8,258,277 | $-8,431,835 |
| Free Cash Flow | |||||
| Operating Cash Flow | 672,101 | 3,195,000 | 2,488,988 | 1,743,620 | 452,969 |
| Capital Expenditure | -38,854 | -397,000 | -127,175 | -60,591 | -23,199 |
| Free Cash Flow | 633,247 | 2,798,000 | 2,361,813 | 1,683,029 | 429,770 |